Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
Advanced imaging reveals how childhood brain tumours grow and spread
Researchers have developed a new preclinical platform for studying aggressive childhood brain tumours, using advanced imaging to show how closely experimental models mirror the disease seen in patients.
Remembering Professor Robin Weiss: a pioneer of viral oncology and former ICR Director
Professor Robin Weiss, recognised as one of the most influential scientists in modern virology and cancer biology, passed away on 27 February 2026.
Study reveals how an editing enzyme causes abnormal gene activity in hormone-driven breast cancer
Researchers have uncovered a previously unknown mechanism that allows breast cancer to exploit day-to-day gene activity to fuel its growth. This finding reveals how hormone-driven breast cancers develop and adapt to treatment.
National breast cancer audit helps inform debate over surgical margins for ductal carcinoma in situ
A large national study has provided some of the strongest evidence yet on how much healthy tissue should be removed when treating ductal carcinoma in situ (DCIS) with breast-conserving surgery – helping to resolve a long-running clinical debate and prompting changes to the Association of Breast Surgeons guidance.